MOTS-c Peptide: The Mitochondrial Peptide With Zero Human Studies
MOTS-c is marketed as an exercise mimetic and metabolic optimizer. In May 2026, FDA reviewers searched the medical literature for clinical studies of MOTS-c in humans and found none. Not few. None. This guide covers what the agency found ahead of the July 23, 2026 advisory committee vote, and what the rodent evidence does and does not support.
Updated July 24, 2026. On July 23 the Pharmacy Compounding Advisory Committee voted 7-5, with two abstentions, to recommend MOTS-c (free base and acetate) for the 503A bulks list, evaluated for obesity and osteoporosis. The panel voted for it despite FDA briefing documents (released June 29, 2026) that recommended against listing on the grounds of no human clinical data, no toxicology package, and inadequate chemical characterization. The vote is a non-binding recommendation, not FDA approval. MOTS-c is still not an FDA-approved drug, no human dose has been established, and any legal compounding pathway is months of rulemaking away.
The Central Fact: No Human Clinical Studies Exist
Start here, because everything else follows from it. In its evaluation for the 503A bulks list, FDA searched PubMed, Embase, the Cochrane Database of Systematic Reviews, DailyMed, Drugs@FDA, and professional and clinical reference sources. The reviewers wrote that they "did not identify clinical studies evaluating administration of MOTS-c-related BDSs in human subjects." The nomination cited 12 literature references; the reviewers noted these "did not include clinical studies."
This is not a case of weak evidence, mixed evidence, or evidence that failed to reach significance. It is an absence. Whatever a person believes MOTS-c does in a human body, no one has published a study measuring it.
We are being explicit about this because a previous version of this guide was not. It stated that fasting glucose typically improves within 2 to 4 weeks, that triglycerides typically decrease 20 to 40 percent, and that some type 2 diabetics reduce medication requirements. Those claims had no human evidence behind them and have been removed. If you read them here before, disregard them.
The FDA 503A Review and the July 23 Vote
The Pharmacy Compounding Advisory Committee meets July 23-24, 2026 at FDA's White Oak campus to evaluate seven peptides for the 503A bulk drug substances list. MOTS-c is on the Day 1 agenda with BPC-157, KPV, and TB-500. Day 2 covers DSIP (emideltide), Semax, and Epitalon.
The uses FDA reviewed for MOTS-c are obesity and osteoporosis. The reviewers' conclusion: "After considering the information currently available, a balancing of the criteria weighs against MOTS-c free base or MOTS-c acetate being placed on that list." The committee disagreed. On July 23, 2026 it voted 7-5, with two abstentions, to recommend MOTS-c for the list, the narrowest margin of the four Day 1 peptides. Our PCAC vote results guide covers the procedure, the docket, and all seven substances.
Context worth holding: the committee vote is advisory. FDA is not bound by it, and adding anything to the list requires formal rulemaking afterward. MOTS-c is not on the list today, so an unfavorable vote preserves the status quo rather than restricting anything.
Why FDA Says MOTS-c Is Not Well Characterized
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, discovered in 2015. The fact that the body produces it endogenously is often offered as evidence of inherent safety. It is not, and the FDA review shows why the two questions are unrelated.
The reviewers found MOTS-c free base not well characterized for two reasons. First, inconsistent naming conventions that do not follow established chemical nomenclature standards such as INN, IUPAC, or USAN. Second, and more consequentially, substance-specific quality control attributes including impurities, aggregates, and endotoxins were not found in the publicly available literature, and the nomination package contained no certificate of analysis establishing identity, purity, or impurity profile.
They added a formulation problem: without water solubility data or a stated reconstitution concentration for the proposed injectable product, it is not possible to judge whether solubility would compromise product performance. Lyophilized MOTS-c free base is reported stable below -20 degrees Celsius, desiccated and protected from light, which is a demanding storage requirement most consumer supply chains do not meet. See our peptide storage guide.
The Toxicology Package Is Empty
For each standard nonclinical safety study type, the FDA review records the same finding. Repeat-dose toxicity: the nominator did not submit and FDA did not identify any. Genotoxicity: none. Developmental and reproductive toxicity: none. Carcinogenicity: none. Four categories, four blanks.
The reviewers summarized the position plainly: "There is a lack of clinical and nonclinical safety information on the use of MOTS-c. FDA is particularly concerned about the lack of human data on drug products containing this substance administered via any route of administration." They noted MOTS-c is a 16-amino-acid peptide "for which there is a lack of information to assess its immunogenic safety risk," and concluded that "potential safety risks associated with the use of MOTS-c in humans are unknown."
Unknown is the operative word. It is not a synonym for low. A peptide with no toxicology package and no human exposure data is not a peptide with a clean record; it is a peptide with no record.
What the Rodent and Cell Evidence Does Show
The preclinical work is not nothing, and it is worth describing accurately. FDA reviewers acknowledged that nonclinical pharmacological studies indicate that in rodent models MOTS-c, acting via AMPK-dependent mechanisms, can according to the study authors improve glucose handling and related metabolic parameters. AMPK is a well-established cellular energy sensor, and its activation is genuinely linked to mitochondrial biogenesis through PGC-1 alpha, to fat oxidation, and to reduced inflammatory signaling.
That is a coherent mechanistic story. The limitation the reviewers identified is that these studies "were limited to in-vitro and in-vivo rodent models," and that dose-response assessments were incomplete. Rodent metabolic models translate to humans poorly and often; the history of obesity drug development is largely a history of compounds that worked in mice and did not work in people.
So the accurate statement is narrow: MOTS-c activates AMPK in rodents and cells, with downstream metabolic effects reported in those models. Everything beyond that sentence, in humans, is speculation. For a peptide with comparable longevity framing but a different mechanism, see NAD+ injections and GHK-Cu.
Approved Alternatives Exist for Both Nominated Uses
FDA flagged that approved drug products already exist for weight reduction in patients with obesity and for treatment of osteoporosis. Under the agency's criteria this weighs against the nomination, because the argument for tolerating an uncharacterized substance is weakest when characterized options are available.
The gap is not subtle. For obesity, GLP-1 receptor agonists carry large randomized trials: semaglutide produced roughly 15 percent body weight reduction at 68 weeks in STEP 1, and tirzepatide up to 22.5 percent in SURMOUNT-1. SURMOUNT-5, the head-to-head trial, reported 20.2 percent weight loss with tirzepatide versus 13.7 percent with semaglutide at week 72. Against zero human studies, that is not a close comparison.
See our guides on retatrutide, orforglipron, and which GLP-1 is best for weight loss for the evidence-backed end of the metabolic peptide space.
Dosing: Every Number Online Is Extrapolated
Circulating MOTS-c protocols typically specify 100 to 200 micrograms subcutaneously once or twice daily, sometimes 200 to 400 micrograms daily split into two injections, sometimes intermittent dosing three to four days weekly justified by a theory that pulsatile AMPK activation is preferable. None of this is derived from human data, because there is no human data. These are conventions, not findings.
The same applies to cycling advice, timing around workouts, and stacking recommendations. An 8-to-12-week on-off cycle is sometimes described as the conservative approach. Conservative relative to what is unclear when the baseline is an uncharacterized substance with an empty toxicology package.
Our MOTS-c dosage guide documents what circulates in practice, with the same caveat: these figures describe what people do, not what has been shown to be safe or effective.
Supply Quality Is a Separate Risk
MOTS-c is not on the 503A bulks list, which means no licensed compounding pharmacy can legally prepare it from bulk for a patient. It reaches US buyers through research-chemical vendors selling material labeled not for human consumption, a market with no obligation to meet pharmaceutical standards for identity, purity, endotoxin limits, or aggregate content.
Stack that on top of the FDA characterization findings and the position is stark: an uncharacterized substance, with no human data and no toxicology, sourced from a channel with no quality obligations, requiring sub-minus-20-degree storage, self-injected at a dose nobody established. See peptide grey market risks, are peptides legal, and compounding pharmacy peptides.
How the July 23 Vote Went
MOTS-c had the thinnest evidence package of the four Day 1 substances. BPC-157 and KPV at least have preclinical and some clinical literature to argue over; MOTS-c has no human studies at all. It became the clearest test of whether the reshaped committee would follow its own reviewers, and it did not: the panel voted 7-5 to recommend it, the narrowest margin of the day.
The vote turned on the nominator presentation, which included testimony from Dr. Pinchas Cohen, who first described MOTS-c and moved it into clinical trials. Members who voted no cited the same gap the FDA staff flagged: no human efficacy or safety data. The recommendation does not resolve that gap; it only sends the question into FDA rulemaking, which can run a year or more.
For the broader regulatory picture, see the 14 peptides reclassification, the FDA 503B GLP-1 exclusion, and the GLP-1 compounding crackdown.
Frequently Asked Questions About MOTS-c
No. This is the single most important fact about MOTS-c and the one most often omitted. In its briefing document dated May 11, 2026, FDA wrote that it performed its own search of the published medical literature and "did not identify clinical studies evaluating administration of MOTS-c-related BDSs in human subjects." The nominator cited 12 references in support; none were clinical studies. Every benefit attributed to injected MOTS-c in humans is an extrapolation from cell cultures and rodents.
FDA reviewers concluded that "a balancing of the criteria weighs against MOTS-c free base or MOTS-c acetate being placed on that list," referring to the 503A bulks list. They found the substance not well characterized chemically, cited a lack of evidence of effectiveness for the nominated uses, and noted the absence of human safety data of any kind. The Pharmacy Compounding Advisory Committee voted against that staff recommendation on July 23, 2026, backing MOTS-c 7-5 with two abstentions. A committee recommendation is not a final agency decision, and it does not change the underlying lack of human data.
Unknown, and the FDA was direct about it: "potential safety risks associated with the use of MOTS-c in humans are unknown." The reviewers found no repeat-dose toxicity studies, no genotoxicity studies, no developmental or reproductive toxicity studies, and no carcinogenicity studies for either MOTS-c free base or MOTS-c acetate. They also flagged that MOTS-c is a 16-amino-acid peptide with no information available to assess its immunogenic risk when injected. The common claim that MOTS-c has a favorable safety profile rests on the absence of studies, not on their results.
There is no human evidence either way. Rodent studies show MOTS-c acting through AMPK-dependent mechanisms with effects on glucose handling, and that work is real. But no clinical study has measured fasting glucose, HOMA-IR, HbA1c, or any other metabolic endpoint in humans receiving MOTS-c. Specific figures circulating online, such as claimed triglyceride reductions of 20 to 40 percent or improvements in fasting glucose within 2 to 4 weeks, do not trace back to any human trial. Treat any numeric human outcome claim about MOTS-c as unsourced.
The July 23, 2026 agenda lists obesity and osteoporosis as the uses FDA reviewed. The underlying nomination was broader, covering insulin resistance, obesity, osteoporosis, vascular calcification, muscle and fat metabolism, and longevity. FDA noted that approved drug products already exist for weight reduction in patients with obesity and for treatment of osteoporosis, which weighs against the nomination under agency criteria.
There is no human evidence supporting MOTS-c for weight loss, and effective approved options exist. If weight loss is the goal, GLP-1 receptor agonists have large randomized trials behind them: roughly 15 percent body weight reduction with semaglutide at 68 weeks in STEP 1 and up to 22.5 percent with tirzepatide in SURMOUNT-1. Choosing an unstudied peptide over drugs with that evidence base is a decision worth examining. Discuss options with a clinician.
That framing comes from rodent work showing MOTS-c activates AMPK and PGC-1 alpha, the same pathways endurance exercise activates. It is a mechanistic parallel, not a demonstrated human effect. No study has measured exercise capacity, endurance, or training adaptation in humans given MOTS-c. Claims that users experience improved stamina and faster recovery are anecdotal reports from unblinded people who purchased the product.
No dose has been established as safe or effective in humans, because no human study exists. Protocols circulating online, typically 100 to 200 micrograms subcutaneously once or twice daily, are not derived from clinical data. FDA also noted a lack of water solubility data and no reconstitution concentration for the proposed injectable product, meaning even basic formulation questions are open. Anyone publishing a MOTS-c dosing chart is extrapolating.
Endogenous production and pharmaceutical characterization are different questions. FDA found MOTS-c free base not well characterized for two reasons: inconsistent naming conventions that do not follow established standards such as INN, IUPAC, or USAN, and the absence in the published literature and the nomination package of the quality-control attributes needed to establish identity, purity, and impurity profiles, including data on impurities, aggregates, and endotoxins, plus no certificate of analysis. Your mitochondria making a peptide says nothing about what is in a vendor vial.
The July 23, 2026 vote (7-5, two abstentions) is advisory and non-binding. FDA can accept, modify, or reject it, and actually adding MOTS-c to the 503A bulks list requires formal notice-and-comment rulemaking that typically takes eight to twelve months or longer. MOTS-c is not on the list today, so nothing changes for now: it remains an unapproved substance with no established human dose. The favorable vote only starts a longer process.